Go offline with the Player FM app!
#32 Scientific Fortune in Prostate Cancer Research with Dr Kieran Scott
Archived series ("Inactive feed" status)
When? This feed was archived on September 20, 2020 04:07 (). Last successful fetch was on August 14, 2020 01:55 ()
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 199719826 series 1455072
Dr Kieran Scott works at the Ingham Institute developing a cancer drug that targets inflammation as a means of treating prostate cancer. Kieran's currently at the clinical trial stage, testing his compound 'C2' on 12 participants. We talked to Kieran about the process of drug development for Prostate cancer, the luck involved in scientific research, as well as the often ill-considered aspects of conducting research.
Note: During the discussion of the Shine Dalgarna sequence in this conversation, Dr Scott mistakenly referred to ribosomes binding to DNA when he intended to say RNA. To clarify the error, the mechanism by which the Shine Dalgarno sequence serves to direct protein translation in bacteria is that the sequence, encoded in DNA prior to the translation start site of a gene is transcribed into mRNA. The ribosome recognises this site and so can initiate translation of the mRNA.
79 episodes
Archived series ("Inactive feed" status)
When? This feed was archived on September 20, 2020 04:07 (). Last successful fetch was on August 14, 2020 01:55 ()
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 199719826 series 1455072
Dr Kieran Scott works at the Ingham Institute developing a cancer drug that targets inflammation as a means of treating prostate cancer. Kieran's currently at the clinical trial stage, testing his compound 'C2' on 12 participants. We talked to Kieran about the process of drug development for Prostate cancer, the luck involved in scientific research, as well as the often ill-considered aspects of conducting research.
Note: During the discussion of the Shine Dalgarna sequence in this conversation, Dr Scott mistakenly referred to ribosomes binding to DNA when he intended to say RNA. To clarify the error, the mechanism by which the Shine Dalgarno sequence serves to direct protein translation in bacteria is that the sequence, encoded in DNA prior to the translation start site of a gene is transcribed into mRNA. The ribosome recognises this site and so can initiate translation of the mRNA.
79 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.